{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:17Z","timestamp":1786116317284,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal antiplatelet bridging strategy before initiating direct oral anticoagulants (DOACs) in patients with acute ischemic stroke (AIS) and non-valvular atrial fibrillation (NVAF) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective cohort study included 120 patients with AIS and NVAF who received antiplatelet therapy prior to DOAC initiation. Patients were stratified by regimen: single antiplatelet therapy (SAPT,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f48) or dual antiplatelet therapy (DAPT,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f72). Primary outcomes included early neurological improvement (\u22652-point NIHSS reduction), early neurological deterioration (\u22654-point NIHSS increase or death within 48\u202fh), and in-hospital bleeding. Secondary outcomes were 90-day favorable functional outcome (modified Rankin Scale 0\u20132), 90-day excellent outcome (mRS 0\u20131), and ordinal mRS shift. Multivariate logistic regression identified independent predictors. Ordinal logistic regression was used for mRS shift analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable between groups, with no significant differences in baseline NIHSS score (median 4.00 vs. 2.00,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.136) or mRS score (median 3.00 vs. 3.00,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.435). No significant differences were observed in early neurological improvement (39.6% vs. 37.5%,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.969), early deterioration (4.2% vs. 0%,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.158), or bleeding events (6.2% vs. 1.4%,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.301). In unadjusted analysis, DAPT demonstrated higher 90-day favorable outcome (90.3% vs. 75.0%,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.046). However, after multivariable adjustment, DAPT was not independently associated with mRS 0\u20132 (adjusted OR 2.40, 95% CI 0.62\u201310.06,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.211), mRS 0\u20131 (adjusted OR 1.18, 95% CI 0.43\u20133.14,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.739), or ordinal mRS shift (adjusted common OR 0.70, 95% CI 0.34\u20131.44,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.336). Baseline NIHSS score independently predicted all outcomes (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001 for all).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In unadjusted analysis, DAPT prior to DOAC initiation was associated with higher 90-day favorable functional outcome without excess bleeding risk. However, this association was not independent of baseline stroke severity after multivariable adjustment, suggesting that the crude benefit was largely attributable to selection bias rather than a true therapeutic advantage of DAPT. The current data do not support the superiority of DAPT over SAPT. Baseline NIHSS score independently predicted both short-term and long-term outcomes. These hypothesis-generating findings warrant confirmation in adequately powered prospective randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1882830","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:08:23Z","timestamp":1786007303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Single vs. dual antiplatelet therapy before DOAC initiation in acute ischemic stroke with atrial fibrillation: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Guan-xin","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adili","family":"Tuersun","sequence":"additional","affiliation":[{"name":"College of Clinical Pharmacy, Shenyang Pharmaceutical University","place":["Shenyang, China"]},{"name":"State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, School of Pharmaceutical Sciences, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-sheng","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-chun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dalian Rehabilitation Recuperation Center of Joint Logistics Support Force of PLA","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-shu","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command of PLA","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(18)30356-9","article-title":"Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation","volume":"18","author":"Seiffge","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0140-6736(25)00676-2","article-title":"Timing of anticoagulation after ischaemic stroke and atrial fibrillation: better swift than sorry","volume":"406","author":"Ziai","year":"2025","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.279.16.1265","article-title":"Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial","volume":"279","year":"1998","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1161\/STR.0000000000000498","article-title":"2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"57","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/01.STR.31.6.1240","article-title":"Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups","volume":"31","author":"Chen","year":"2000","journal-title":"Stroke"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European stroke organisation guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non\u2013vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study","volume":"146","author":"Oldgren","year":"2022","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2024.1450","article-title":"Early vs late anticoagulation in minor, moderate, and major ischemic stroke with atrial fibrillation: post hoc analysis of the ELAN randomized clinical trial","volume":"81","author":"Goeldlin","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(24)02197-4","article-title":"Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial","volume":"404","author":"Werring","year":"2024","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.53.1.126","article-title":"Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the trial of org 10172 in acute stroke treatment (TOAST)","volume":"53","author":"Adams","year":"1999","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1882830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:08:24Z","timestamp":1786007304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1882830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":16,"alternative-id":["10.3389\/fneur.2026.1882830"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1882830","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1882830"}}